Lipoproteins and the pathogenesis of atherosclerosis : proceedings of the International Symposium on Lipoproteins and the Pathogenesis of Atherosclerosis, Gleneagles, Perthshire, 24-27 February 1991
著者
書誌事項
Lipoproteins and the pathogenesis of atherosclerosis : proceedings of the International Symposium on Lipoproteins and the Pathogenesis of Atherosclerosis, Gleneagles, Perthshire, 24-27 February 1991
(International congress series, no. 970)
Excerpta Medica, 1991
大学図書館所蔵 全7件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
注記
Includes bibliographical references and index
内容説明・目次
内容説明
Lipoprotein disorders are among the most common metabolic derangements encountered in industrialised countries. Figures for the United States of America, for example, reveal that more than half of the adult population have too high plasma cholesterol levels. It is not surprising that ischaemic heart disease remains the commonest cause of death in the western world. This volume focuses on the origin of the problem by exploring the factors which govern the structure and metabolism of human plasma lipoproteins and those which regulate lipoprotein interaction with the developing atherosclerotic lesion. Secondly, recent advances in the pharmaceutical industry have led to the development of powerful and effective new lipid lowering drugs. The practising physician needs to know when to use these agents and what to expect of them. This topic is examined in some detail to provide a basis for rational lipid lowering pharmacotherapy if dietary intervention fails. The implementation of effective intervention programs offers the prospect of reducing the impact of heart disease and improving the quality and expectation of life in the community.
目次
DNA: Genetic basis of hyperlipidaemia and atherosclerosis risk Apolipoprotein B-100 metabolism in normolipidaemic subjects homozygous for different apolipoprotein E isoforms (T. Demant, D. Bedford, C.J. Packard, J. Shepherd). Familial defective apolipoprotein B-100: Clinical characteristics and frequency (A. Tybjaerg-Hansen). Strategies to identify common, functionally important sequence polymorphisms in the apo B gene (S. Humphries, A. Dunning, C.F. Xu, P. Talmud). Genetic variants of lipoprotein lipase relate to hyperlipidaemia and premature atherosclerosis (D.J. Galton et al.). An association between the apo A-I G/A polymorphism and hyperlipidemia in a free living population. (A.M. Cumming, A.S.F. Doney). Triglycerides and atherosclerosis Lipases in lipoprotein metabolism (T. Olivecrona, G. Bengtsson-Olivecrona, M. Hultin). Diabetes and hypertriglyceridemia (M.-R. Taskinen). Postprandial lipoprotein metabolism and high density lipoproteins (J.R. Patsch, H. Braunsteiner). Postprandial lipoprotein metabolism in normolipidemic males with and without coronary artery disease (P.H.E. Groot et al.). Fibrates and postprandial lipaemia (C.J. Packard, H. Simpson, J. Shepherd). Novel markers for atherosclerosis Therapeutic implications of raised levels of lipoprotein (a) (G.R. Thompson). The substructure of HDL and its relevance to atherosclerosis (P.J. Barter). CETP and the regulation of plasma HDL (D.J. Freeman). New ideas about the role of HDL (P.N. Durrington). Cholesterol metabolism The atherosclerotic plaque (M.J. Davies). Lipoproteins and monocyte recruitment in early atherosclerosis (A.J. Lusis, J.A. Berliner, A.M. Fogelman) HMG CoA reductase inhibitors: The magic bullets for hypercholesterolemia? (D.R. Illingworth). Altered platelet and rheological parameters in familial hypercholesterolaemia (D.J. Betteridge et al.). The West of Scotland Coronary Prevention Trial Progress and prospects (The West of Scotland Coronary Prevention Group). Index of authors
「Nielsen BookData」 より